Peptide bioregulators: Khavinson’s short peptides and the evidence

The bioregulator hypothesis, developed from the 1970s onward by Vladimir Khavinson and colleagues in Leningrad (St Petersburg), is that each tissue produces its own very short regulatory peptides, and that these decline with age. Replacing them — first with purified tissue extracts, later with synthetic copies of the active sequences — was proposed to restore gene expression and protein synthesis toward a younger pattern in that tissue[1].

The early preparations were extracts: Epithalamin from the pineal gland and Thymalinfrom the thymus. The group then identified and synthesised short sequences meant to reproduce their effects. The two most studied are Epitalon (Ala-Glu-Asp-Gly), modelled on Epithalamin, and Pinealon(Glu-Asp-Arg, the "EDR" peptide), studied for brain tissue. Biophysical and review work proposes that such short peptides can enter cells and interact with DNA and chromatin — a mechanism still debated[8].

It is an unusual idea by Western pharmacology standards, and the literature is concentrated in a few Russian and Ukrainian institutes. It is also one of the very few peptide programmes in the world to have followed older people for more than a decade.

Six to eight years, 266 people. Researchers at the St Petersburg Institute of Bioregulation and Gerontology and the Institute of Gerontology in Kyiv followed 266 elderly and older people who received Thymalin, Epithalamin or both during the first two to three years. The treated groups reported fewer acute respiratory illnesses and cardiovascular events, and mortality over the observation period was 1.6–1.8-fold lower with Epithalamin and 2.5-fold lower with the combination than in controls[2].

Twelve years, accelerated ageing. A 12-year randomised clinical study gave Epithalamin to elderly patients with coronary disease and accelerated cardiovascular ageing. After 12 years, deaths in the treated group were 28% lower than in controls on the same basic therapy, and cardiovascular mortality was half[3].

Melatonin rhythm. In ageing monkeys and elderly people, both Epithalamin and synthetic Epitalon were reported to restore night-time melatonin release and normalise its daily rhythm[4] — which is why Epitalon scores on the Sleep axis of our radar. A comparative Russian study of geroprotective methods included Pinealon among the interventions assessed on biological-age markers[10].

Cells and animals. Epitalon induced telomerase activity and telomere elongation in cultured human somatic cells[5], and a 2025 review in the International Journal of Molecular Sciences summarises its wider bioactivity[6]. Pinealon increased cell viability by suppressing free radicals in culture[7] and was studied in 18-month-old rats under hypoxia[9].

The caveat. These are human results and our radar counts them as such. But the cohorts are small by modern standards, the reporting is brief, and replication outside the originating institutes is scarce. Read them as a serious signal that has not yet been independently tested.

The Khavinson catalogue runs to dozens of tissue-specific peptides — Thymalin and its synthetic analogues for the thymus, and short peptides proposed for vessels, liver, cartilage and retina. We only list a compound once we hold a batch with its own purity certificate. For now the range is Epitalon, Pinealon and the Cerebral Bioregulator Stack; see Thymalin in the glossary for the thymus work.